The STAR-RA cohort study did not demonstrate a significant cardiovascular and neoplastic increased risk with TOFA compared to TNF inhibitors, even in patients over 50 years of age with at least one cardiovascular risk factor [58,59]. This evidence concerns the gene TNF and rheumatoid arthritis.